There’s no easy answer for how to solve the opioid crisis that has cost the U.S. over $37 billion since 2000.
But Robert Kramer, the CEO of Emergent Biosolutions, a biopharmaceutical company responsible for overdose reversal drug Naloxone, laid out three areas that require renewed attention.
